Proton-pump inhibitor use and hip fractures in men: a population-based case-control study

Adams, Annette L.; Black, Maureen M.; Zhang, Jian L.; Shi, Jiaxiao; Jacobsen, Steven J.

doi:10.1016/j.annepidem.2014.01.004

Cited by 45 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our finding concerning short‐term current PPI use and increased risk of hip fracture, is in line with previous case‐control studies conducted among general population, which all reported the slightly increased risk in current use but no significant risk in long‐term or cumulative use. In addition, the study of Adams et al, which was restricted to men only, reported the highest risk at the beginning of the treatment which is consistent with our results . The highest risk during short‐term PPI use might be explained so that PPIs are prescribed to persons with high risk for falling because of their unstable health condition.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study

Torvinen-Kiiskinen

Tolppanen

Koponen

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Hip fractures are a major health concern among older persons with Alzheimer's disease, who usually use many concomitant drugs for several diseases. Evidence of the association between proton pump inhibitor use and risk of hip fracture is contradictory. Aim To investigate whether the long‐term use of proton pump inhibitor is associated with risk of hip fractures among community‐dwelling persons with Alzheimer's disease. Methods In this nested case‐control study, the nationwide MEDALZ data were utilised. Community‐dwelling persons with Alzheimer's disease who encountered incident hip fracture (N = 4818; mean age 84.1) were included as cases. Four controls were matched for each case at the date of hip fracture (N = 19 235; mean age 84.0). The association between hip fracture and duration of current PPI use (ongoing use during 0‐30 days before the index date), and cumulative duration of use during 10 years before was investigated with conditional logistic regression. Results Long‐term or cumulative proton pump inhibitor use was not associated with an increased risk of hip fracture. Current proton pump inhibitor use was associated with an increased risk of hip fracture (adjusted OR 1.12, 95% CI 1.03‐1.22). The risk was increased in short‐term current use (<1 year) (adjusted OR 1.23, 95% CI 1.10‐1.37). Conclusions The increased risk of hip fracture was evident only in short‐term proton pump inhibitor use, but no association was found for long‐term or cumulative use. Thus, our findings do not support previous assumptions that long‐term proton pump inhibitor use would be associated with an increased risk of hip fractures.

show abstract

Section: Discussionsupporting

confidence: 91%

“…Our study found no differences between drug substances and risk of hip fracture. Three previous studies have reported differences between drug substances . Two found an increased risk associated with omeprazole use compared to non‐use of omeprazole, and one found no significant differences …”

Section: Discussionmentioning

confidence: 89%

Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study

Torvinen-Kiiskinen

Tolppanen

Koponen

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…In a meta-analysis by Kwok et al [7], increased duration of PPI use was associated with higher risk ratios for fractures. Two more recent studies showed evidence for an increased fracture risk after long-term PPI use in older adults [10,37]. In contrast, a study by Soriano et al [38] showed a higher hip fracture risk after short-term PPI use, but not after long-term PPI use.…”

Section: Discussionmentioning

confidence: 98%

The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study

Hoorn

Tett

Vries

et al. 2015

Bone

View full text Add to dashboard Cite

Please cite this article as: van der Hoorn Mariëlle M.C., Tett Susan E., de Vries Oscar J., Dobson Annette J., Peeters G.M.E.E. (Geeske), The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study, Bone (2015Bone ( ), doi: 10.1016Bone ( /j.bone.2015 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT 2 ABSTRACT Objectives:Proton pump inhibitors (PPIs) are among the most prescribed medications worldwide, however, there is growing concern regarding potential negative effects on bone health. The aim was to examine the effect of dose and type of PPI use on subsequent use of osteoporosis medication and fractures in older Australian women. Methods:Data were included from 4432 participants (born 1921-26) Conclusion:An appropriate benefit/risk assessment should be made when prescribing PPIs, especially for esomeprazole and rabeprazole, as osteoporosis and fracture risks were increased in this cohort of elderly females subsequent to PPI prescription. Highlights Proton pump inhibitor (PPI) use in elderly (>77 years) women was associated with increased risk of decreased bone health. Increased risk of subsequent osteoporosis medication was associated with the most commonly prescribed PPI, esomeprazole, and with rabeprazole and use of multiple different PPIs.

show abstract

“…Proton pump inhibitor medications are among the most commonly used drugs in the United States today. 22 Admission to the hospital Bernardo J. Reyes, MD and Simon C. Mears, MD, PhD Typically, a patient with an acute hip fracture is unable to walk, is seen in the emergency department (ED), admitted to the hospital, and then the fracture is surgically repaired. Despite the seeming simplicity of this pathway, many roadblocks stand in the way of optimal care.…”

Section: Hip Fractures Stephen Kates MDmentioning

confidence: 99%

A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2

Mears¹,

Kates²

2015

Geriatr Orthop Surg Rehabil

133

121

View full text Add to dashboard Cite

Over the past 4 decades, much has been learned about the pathophysiology and treatment of osteoporosis, the prevention of fragility fractures, and the perioperative management of patients who have these debilitating injuries. However, the volume of published literature on this topic is staggering and far too voluminous for any clinician to review and synthesize by him or herself. This manuscript thoroughly summarizes the latest research on fragility fractures and provides the reader with valuable strategies to optimize the prevention and management of these devastating injuries. The information contained in this article will prove invaluable to any health care provider or health system administrator who is involved in the prevention and management of fragility hip fractures. As providers begin to gain a better understanding of the principles espoused in this article, it is our hope that they will be able to use this information to optimize the care they provide for elderly patients who are at risk of or who have osteoporotic fractures.

show abstract

Proton-pump inhibitor use and hip fractures in men: a population-based case-control study

Cited by 45 publications

References 25 publications

Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study

Proton pump inhibitor use and risk of hip fractures among community‐dwelling persons with Alzheimer's disease—a nested case‐control study

The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study

A Guide to Improving the Care of Patients with Fragility Fractures, Edition 2

Contact Info

Product

Resources

About